Table 3:
Associations between biologics/tsDMARDs and glucocorticoids with mortality and readmission
| 90-Day Mortality | 30-Day Readmission | ||||||
|---|---|---|---|---|---|---|---|
| N | Mortality N (%) | Unadjusted OR (95% CI) | Propensity weighted OR (95% CI) | Readmission N (%)* | Unadjusted OR (95% CI) | Propensity weighted OR (95% CI) | |
| Methotrexate | 6194 | 401 (6.5%) | Reference | Reference | 781/5690 (13.7%) | Reference | Reference |
| TNF | 3523 | 134 (3.8%) | 0.57 (0.47–0.70) | 0.83 (0.67–1.02) | 367/3295 (11.1%) | 0.79 (0.69–0.90) | 0.86 (0.75–0.993) |
| Non-TNF biologic/tsDMARD | 1060 | 42 (4.0%) | 0.60 (0.43–0.82) | 0.78 (0.49–1.22) | 134/992 (13.5%) | 0.98 (0.81–1.20) | 1.02 (0.78–1.33) |
| Glucocorticoids† | |||||||
| None | 5720 | 252 (4.4%) | Reference | Reference | 596/5329 (11.2%) | Reference | Reference |
| ≤5mg/day | 3137 | 181 (5.8%) | 1.33 (1.09–1.62) | 1.20 (0.98–1.48) | 386/2893 (13.3%) | 1.22 (1.07–1.40) | 1.10 (0.96–1.27) |
| 5–10mg/day | 1459 | 106 (7.3%) | 1.70 (1.34–2.15) | 1.41 (1.08–1.82) | 216/1336 (16.2%) | 1.53 (1.29–1.81) | 1.26 (1.05–1.52) |
| >10mg/day | 461 | 38 (8.2%) | 1.95 (1.37–2.78) | 1.64 (1.02–2.64) | 84/419 (20.0%) | 1.99 (1.54–2.57) | 1.60 (1.15–2.24) |
Propensity weighted odds ratios (OR) from inverse probability weighted logistic regression models with separate analyses for methotrexate vs. biologics/tsDMARDs and for glucocorticoids. Propensity score models include all covariates shown in online supplementary Table S2. Glucocorticoid propensity score models also include use of methotrexate or type of biologic/tsDMARD and time of last prescription/infusion before surgery. Unbalanced covariates are included in weighed models.
Readmission within 30 days of discharge reported among patients discharged to home, home health, skilled nursing facility, or inpatient rehabilitation
Glucocorticoid dose is the average daily dose in the 3 months prior to surgery.
TNF = tumor necrosis factor inhibitor, tsDMARD = targeted synthetic disease modifying anti-rheumatic drug